Aspirin use reduces the risk of aggressive prostate cancer and disease recurrence in African-American men

Cancer Epidemiology Biomarkers and Prevention

Volumn 26, Issue 6, 2017, Pages 845-853

  Smith, Cheryl Jacobs ^a   Dorsey, Tiffany H ^a   Tang, Wei ^a   Jordan, Symone V ^a   Loffredo, Christopher A ^b   Ambs, Stefan ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b GEORGETOWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANACIN; ASCRIPTIN; C REACTIVE PROTEIN; EXCEDERIN; UNCLASSIFIED DRUG; NONSTEROID ANTIINFLAMMATORY AGENT;

ADULT; ADVANCED CANCER; AFRICAN AMERICAN; ARTICLE; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CASE CONTROL STUDY; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DRUG USE; EARLY CANCER; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN BLOOD LEVEL; RECURRENCE RISK; RISK REDUCTION; AGED; DISEASE EXACERBATION; PATHOLOGY; PROSTATE TUMOR; RISK FACTOR; TUMOR RECURRENCE;

AFRICAN AMERICANS; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; CASE-CONTROL STUDIES; DISEASE PROGRESSION; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROSTATIC NEOPLASMS; RISK FACTORS;

EID: 85020223819     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-16-1027     Document Type: Article

References (53)

1. Powell IJ. Epidemiology and pathophysiology of prostate cancer in African-American men. J Urol 2007;177:444-9.
2. Rebbeck TR, Devesa SS, Chang BL, Bunker CH, Cheng I, Cooney K, et al. Global patterns of prostate cancer incidence, aggressiveness, and mortality in men of african descent. Prostate Cancer 2013;2013:560857.
3. DeSantis CE, Siegel RL, Sauer AG, Miller KD, Fedewa SA, Alcaraz KI, et al. Cancer statistics for African Americans, 2016: Progress and opportunities in reducing racial disparities. CA Cancer J Clin 2016;66:290-308.
4. Carpten J, Nupponen N, Isaacs S, Sood R, Robbins C, Xu J, et al. Germline mutations in the ribonuclease L gene in families showing linkage with HPC1. Nat Genet 2002;30:181-4.
5. Freedman ML, Haiman CA, Patterson N, McDonald GJ, Tandon A, Waliszewska A, et al. Admixture mapping identifies 8q24 as a prostate cancer risk locus in African-American men. Proc Natl Acad Sci USA 2006;103:14068-73.
6. Robbins C, Torres JB,Hooker S, Bonilla C, HernandezW, Candreva A, et al. Confirmation study of prostate cancer risk variants at 8q24 in African Americans identifies a novel risk locus. Genome Res 2007;17:1717-22.
7. Powell IJ, Bock CH, Ruterbusch JJ, Sakr W. Evidence supports a faster growth rate and/or earlier transformation to clinically significant prostate cancer in black than in white American men, and influences racial progression and mortality disparity. J Urol 2010;183:1792-6.
8. Martin DN, Starks AM, Ambs S. Biological determinants of health disparities in prostate cancer. Curr Opin Oncol 2013;25:235-41.
9. Farrell J, Petrovics G, McLeod DG, Srivastava S. Genetic and molecular differences in prostate carcinogenesis between African American and Caucasian American men. Int J Mol Sci 2013;14:15510-31.
10. Khani F, Mosquera JM, Park K, Blattner M, O'Reilly C, MacDonald TY, et al. Evidence for molecular differences in prostate cancer between African American and Caucasian men. Clin Cancer Res 2014;20:4925-34.
11. De Marzo AM, Platz EA, Sutcliffe S, Xu J, Gronberg H, Drake CG, et al. Inflammation in prostate carcinogenesis. Nat Rev Cancer 2007;7:256-69.
12. Gurel B, Lucia MS, Thompson IM Jr., Goodman PJ, Tangen CM, Kristal AR, et al. Chronic inflammation in benign prostate tissue is associated with high-grade prostate cancer in the placebo arm of the prostate cancer prevention trial. Cancer Epidemiol Biomarkers Prev 2014; 23:847-56.
13. Klink JC, Banez LL, Gerber L, Lark A, Vollmer RT, Freedland SJ. Intratumoral inflammation is associated with more aggressive prostate cancer. World J Urol 2013;31:1497-503.
14. Wallace TA, Prueitt RL, Yi M, Howe TM, Gillespie JW, Yfantis HG, et al. Tumor immunobiological differences in prostate cancer between African-American and European-American men. Cancer Res 2008;68:927-36.
15. Powell IJ, Dyson G, Land S, Ruterbusch J, Bock CH, Lenk S, et al. Genes associated with prostate cancer are differentially expressed in African American and European American men. Cancer Epidemiol Biomarkers Prev 2013;22:891-7.
16. Rose AE, Satagopan JM, Oddoux C, Zhou Q, Xu R, Olshen AB, et al. Copy number and gene expression differences between African American and Caucasian American prostate cancer. J Transl Med 2010;8:70.
17. Hardiman G, Savage SJ, Hazard ES, Wilson RC, Courtney SM, Smith MT, et al. Systems analysis of the prostate transcriptome in African-American men compared with European-American men. Pharmacogenomics 2016;17:1129-43.
18. Eastham JA, May RA, Whatley T, Crow A, Venable DD, Sartor O. Clinical characteristics and biopsy specimen features in African-American and white men without prostate cancer. J Natl Cancer Inst 1998;90:756-60.
19. Vidal AC, Chen Z, Howard LE, Moreira DM, Castro-Santamaria R, Andriole GL, et al. Racial differences in prostate inflammation: results from the REDUCE study. Oncotarget 2016 Jul 18. [Epub ahead of print].
20. Liu Y, Chen JQ, Xie L, Wang J, Li T,He Y, et al. Effect of aspirin and other non-steroidal anti-inflammatory drugs on prostate cancer incidence and mortality: A systematic review and meta-analysis. BMC Med 2014; 12:55.
21. Dhillon PK, Kenfield SA, Stampfer MJ, Giovannucci EL. Long-term aspirin use and the risk of total, high-grade, regionally advanced and lethal prostate cancer in a prospective cohort of health professionals, 1988-2006. Int J Cancer 2011;128:2444-52.
22. Zaorsky NG, Buyyounouski MK, Li T, Horwitz EM. Aspirin and statin nonuse associated with early biochemical failure after prostate radiation therapy. Int J Radiat Oncol Biol Phys 2012;84:e13-7.
23. Choe KS, Cowan JE, Chan JM, Carroll PR, D'Amico AV, Liauw SL. Aspirin use and the risk of prostate cancer mortality in men treated with prostatectomy or radiotherapy. J Clin Oncol 2012;30:3540-4.
24. Jacobs EJ, Newton CC, Gapstur SM, Thun MJ. Daily aspirin use and cancer mortality in a large US cohort. J Natl Cancer Inst 2012;104:1208-17.
25. Dhillon PK, Kenfield SA, Stampfer MJ, Giovannucci EL, Chan JM. Aspirin use after a prostate cancer diagnosis and cancer survival in a prospective cohort. Cancer Prev Res (Phila) 2012;5:1223-8.
26. Flahavan EM, Bennett K, Sharp L, Barron TI. A cohort study investigating aspirin use and survival in men with prostate cancer. Ann Oncol 2014; 25:154-9.
27. Jacobs CD, Chun SG, Yan J, Xie XJ, Pistenmaa DA, Hannan R, et al. Aspirin improves outcome in high risk prostate cancer patients treated with radiation therapy. Cancer Biol Ther 2014;15:699-706.
28. Cardwell CR, Flahavan EM, Hughes CM, Coleman HG, O'Sullivan JM, Powe DG, et al. Low-dose aspirin and survival inmen with prostate cancer: A study using the UK Clinical Practice Research Datalink. Cancer Causes Control 2014;25:33-43.
29. Vidal AC, Howard LE, Moreira DM, Castro-Santamaria R, Andriole GL, Freedland SJ. Aspirin, NSAIDs, and risk of prostate cancer: Results from the REDUCE study. Clin Cancer Res 2015;21:756-62.
30. Veitonmaki T, Tammela TL, Auvinen A, Murtola TJ. Use of aspirin, but not other non-steroidal anti-inflammatory drugs is associated with decreased prostate cancer risk at the population level. Eur J Cancer 2013;49:938-45.
31. Olivo-Marston SE, Yang P, Mechanic LE, Bowman ED, Pine SR, Loffredo CA, et al. Childhood exposure to secondhand smoke and functional mannose binding lectin polymorphisms are associated with increased lung cancer risk. Cancer Epidemiol Biomarkers Prev 2009;18:3375-83.
32. Osborn VW, Chen SC, Weiner J, SchwartzD, Schreiber D. Impact of aspirin on clinical outcomes for African American men with prostate cancer undergoing radiation. Tumori 2016;102:65-70.
33. Magi-Galluzzi C, Tsusuki T, Elson P, Simmerman K, Lafargue C, Esgueva R, et al. TMPRSS2-ERG gene fusion prevalence and class are significantly different in prostate cancer of Caucasian, African-American and Japanese patients. Prostate 2011;71:489-97.
34. Yamoah K, Johnson MH, Choeurng V, Faisal FA, Yousefi K, Haddad Z, et al. Novel biomarker signature that may predict aggressive disease in African American men with prostate cancer. J Clin Oncol 2015; 33:2789-96.
35. Petrovics G, Li H, Stumpel T, Tan SH, Young D, Katta S, et al. A novel genomic alteration of LSAMP associates with aggressive prostate cancer in African American men. EBioMedicine 2015;2:1957-64.
36. Faisal FA, Sundi D, Tosoian JJ, Choeurng V, Alshalalfa M, Ross AE, et al. Racial variations in prostate cancer molecular subtypes and androgen receptor signaling reflect anatomic tumor location. Eur Urol 2015;70: 14-7.
37. Khera A, McGuire DK, Murphy SA, Stanek HG, Das SR, Vongpatanasin W, et al. Race and gender differences in C-reactive protein levels. J Am Coll Cardiol 2005;46:464-9.
38. Morimoto Y, Conroy SM, Ollberding NJ, Kim Y, Lim U, Cooney RV, et al. Ethnic differences in serum adipokine and C-reactive protein levels: The multiethnic cohort. Int J Obes (Lond) 2014;38:1416-22.
39. Liu ZQ,Chu L, Fang JM, Zhang X, Zhao HX, Chen YJ, et al. Prognostic role of C-reactive protein in prostate cancer: A systematic review and meta-analysis. Asian J Androl 2014;16:467-71.
40. Rocha P, Morgan CJ, Templeton AJ, Pond GR, Naik G, Sonpavde G. Prognostic impact of C-reactive protein in metastatic prostate cancer: A systematic review and meta-analysis. Oncol Res Treat 2014;37:772-6.
41. Van Hemelrijck M, Jungner I, Walldius G, Garmo H, Binda E, Hayday A, et al. Risk of prostate cancer is not associated with levels of C-reactive protein and other commonly used markers of inflammation. Int J Cancer 2011;129:1485-92.
42. Allin KH, Bojesen SE, Nordestgaard BG. Inflammatory biomarkers and risk of cancer in 84,000 individuals from the general population. Int J Cancer 2016;139:1493-500.
43. FeldmanM, Jialal I, Devaraj S, Cryer B. Effects of low-dose aspirin on serum C-reactive protein and thromboxane B2 concentrations: A placebo-controlled study using a highly sensitive C-reactive protein assay. J Am Coll Cardiol 2001;37:2036-41.
44. Kim MA, Kim CJ, Seo JB, Chung WY, Kim SH, Zo JH, et al. The effect of aspirin on C-reactive protein in hypertensive patients. Clin Exp Hypertens 2011;33:47-52.
45. Mahmud SM, Franco EL, Aprikian AG. Use of nonsteroidal anti-inflammatory drugs and prostate cancer risk: A meta-analysis. Int J Cancer 2010;127:1680-91.
46. Huang TB, Yan Y, Guo ZF, Zhang XL, Liu H, Geng J, et al. Aspirin use and the risk of prostate cancer: A meta-analysis of 24 epidemiologic studies. Int Urol Nephrol 2014;46:1715-28.
47. Jacobs EJ, Thun MJ, Bain EB, Rodriguez C, Henley SJ, Calle EE. A large cohort study of long-term daily use of adult-strength aspirin and cancer incidence. J Natl Cancer Inst 2007;99:608-15.
48. Shebl FM, Sakoda LC, Black A, Koshiol J, Andriole GL, Grubb R, et al. Aspirin but not ibuprofen use is associated with reduced risk of prostate cancer: A PLCO study. British J Cancer 2012;107:207-14.
49. Salinas CA, Kwon EM, FitzGerald LM, Feng Z, Nelson PS, Ostrander EA, et al. Use of aspirin and other nonsteroidal antiinflammatory medications in relation to prostate cancer risk. Am J Epidemiol 2010;172:578-90.
50. Cao Y, Nishihara R, Wu K, Wang M, Ogino S, Willett WC, et al. Populationwide impact of long-term use of aspirin and the risk for cancer. JAMA Oncol 2016;2:762-9.
51. Veitonmaki T, Murtola TJ, Maattanen L, Taari K, Stenman UH, Tammela TL, et al. Prostate cancer risk and nonsteroidal antiinflammatory drug use in the Finnish prostate cancer screening trial. British J Cancer 2014;111:1421-31.
52. Chang SL, Harshman LC, Presti JC Jr. Impact of common medications on serum total prostate-specific antigen levels: Analysis of the National Health and Nutrition Examination Survey. J Clin Oncol 2010;28:3951-7.
53. Coyle C, Cafferty FH, Rowley S, MacKenzie M, Berkman L, Gupta S, et al. ADD-ASPIRIN: A phase III, double-blind, placebo controlled, randomised trial assessing the effects of aspirin on disease recurrence and survival after primary therapy in common non-metastatic solid tumours. Contemp Clin Trials 2016;51:56-64.